# Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals

> **NCT04681430** · PHASE2 · COMPLETED · sponsor: **Heinrich-Heine University, Duesseldorf** · enrollment: 22 (actual)

## Conditions studied

- Corona Virus Infection
- SARS-CoV-2 Infection
- SARS-CoV-2 PCR Test Positive
- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **BIOLOGICAL:** Convalescent plasma
- **DRUG:** Camostat Mesilate
- **DRUG:** Placebo for Camostat Mesilate
- **OTHER:** Standard of Care (SoC)

## Key facts

- **NCT ID:** NCT04681430
- **Lead sponsor:** Heinrich-Heine University, Duesseldorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-08
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04681430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04681430, "Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04681430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*